Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1983 1
1984 2
1985 3
1986 3
1987 1
1988 1
1989 1
1990 2
1991 3
1992 1
1993 5
1994 2
1995 5
1996 3
1997 4
1998 5
1999 3
2000 5
2001 5
2002 6
2003 7
2004 15
2005 7
2006 7
2007 10
2008 16
2009 15
2010 24
2011 37
2012 37
2013 34
2014 41
2015 54
2016 42
2017 69
2018 65
2019 62
2020 77
2021 85
2022 69
2023 70
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

799 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Neuroendocrine Neoplasm"
Page 1
Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Hodi FS, et al. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525992 Free PMC article. Clinical Trial.
METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients) …
METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while t …
Melanom.
Ugurel S, Gutzmer R. Ugurel S, et al. J Dtsch Dermatol Ges. 2023 Apr;21(4):343-347. doi: 10.1111/ddg.15053. Epub 2023 Mar 31. J Dtsch Dermatol Ges. 2023. PMID: 36999586 Review.
Melanoma is a highly aggressive skin tumor nicknamed "black cancer of the skin" because it originates from the pigment-forming cells (melanocytes). The tumors are prone to invasive growth and early lymphogenic and hematogenic metastasis. ...This mini-review does not claim …
Melanoma is a highly aggressive skin tumor nicknamed "black cancer of the skin" because it originates from the pigment-forming cells (melano …
Everolimus.
Hasskarl J. Hasskarl J. Recent Results Cancer Res. 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. Recent Results Cancer Res. 2018. PMID: 30069763 Review.
The mTOR pathway regulates cell growth, proliferation and survival, and is frequently deregulated in cancer.The EMA has approved Everolimus as Afinitor() for the treatment of hormone receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in p …
The mTOR pathway regulates cell growth, proliferation and survival, and is frequently deregulated in cancer.The EMA has approved Everolimus …
Management of neuroendocrine tumor liver metastases.
Harrelson A, Wang R, Stewart A, Ingram C, Gillis A, Rose JB, El-Rayes B, Azmi A, Chen H. Harrelson A, et al. Am J Surg. 2023 Nov;226(5):623-630. doi: 10.1016/j.amjsurg.2023.08.011. Epub 2023 Aug 16. Am J Surg. 2023. PMID: 37657968 Review.
BACKGROUND: Neuroendocrine Tumors (NETs) are a group of tumors that arise from neuroendocrine cells, and are increasing in incidence worldwide. These tumors often metastasize to the liver, and management of these neuroendocrine tumor live …
BACKGROUND: Neuroendocrine Tumors (NETs) are a group of tumors that arise from neuroendocrine cells, and are inc …
Melanoma immunotherapy.
Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Sanlorenzo M, et al. Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi: 10.4161/cbt.28555. Epub 2014 Mar 20. Cancer Biol Ther. 2014. PMID: 24651672 Free PMC article. Review.
Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a treatment in advanced (unresectable or metastatic) stages. Development of novel therapeutic approaches and the optimization of existi …
Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a …
Pancreatic neuroendocrine tumors.
Perri G, Prakash LR, Katz MHG. Perri G, et al. Curr Opin Gastroenterol. 2019 Sep;35(5):468-477. doi: 10.1097/MOG.0000000000000571. Curr Opin Gastroenterol. 2019. PMID: 31306159 Review.
PURPOSE OF REVIEW: Pancreatic neuroendocrine tumors (pNETs) are a rare, heterogeneous group of pancreatic neoplasms with a wide range of malignant potential. They may manifest as noninfiltrative, slow-growing tumors, locally invasive masses, or even swiftly m …
PURPOSE OF REVIEW: Pancreatic neuroendocrine tumors (pNETs) are a rare, heterogeneous group of pancreatic neoplasms with a wid …
Cutaneous Malignancies of the Head and Neck.
In GK, Thomas JS, Silk AW. In GK, et al. Hematol Oncol Clin North Am. 2021 Oct;35(5):991-1008. doi: 10.1016/j.hoc.2021.05.008. Epub 2021 Jul 16. Hematol Oncol Clin North Am. 2021. PMID: 34281755 Review.
Beginning with melanoma, immunotherapy has increasingly been used over the past decade for treatment of unresectable CM, and immune checkpoint inhibitors are now Food and Drug Administration-approved for first-line treatment of unresectable melanoma, Merkel cell car …
Beginning with melanoma, immunotherapy has increasingly been used over the past decade for treatment of unresectable CM, and immune c …
The Evolving Landscape of Neuroendocrine Tumors.
Russo A, Gangi A. Russo A, et al. Surg Oncol Clin N Am. 2023 Jan;32(1):185-198. doi: 10.1016/j.soc.2022.08.003. Epub 2022 Nov 3. Surg Oncol Clin N Am. 2023. PMID: 36410917 Review.
Neuroendocrine tumors (NETs) represent a heterogeneous group of tumors, with variable presentation based on the location of origin and degree of metastatic spread. ...Robust prospective randomized data exists to support the use of medical therapies to improve …
Neuroendocrine tumors (NETs) represent a heterogeneous group of tumors, with variable presentation based on the locatio …
Metastatic liver tumors.
McCarter MD, Fong Y. McCarter MD, et al. Semin Surg Oncol. 2000 Sep-Oct;19(2):177-88. doi: 10.1002/1098-2388(200009)19:2<177::aid-ssu9>3.0.co;2-s. Semin Surg Oncol. 2000. PMID: 11126381 Review.
The data regarding liver resection for other metastatic tumor types are less clear. However, resection for selected tumors, such as neuroendocrine and renal cell, can provide durable palliation and/or cure. ...The role of adjuvant regional and systemic chemotherapy …
The data regarding liver resection for other metastatic tumor types are less clear. However, resection for selected tumors, such as …
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Dummer R, et al. Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9. Lancet Oncol. 2017. PMID: 28284557 Clinical Trial.
METHODS: NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS-mutant melanoma who were previously untreated or had progressed on …
METHODS: NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresect …
799 results